Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics

被引：0
|
作者：
窦雪琳 [1 ]
机构：
[1] Peking Univ People’s Hosp,Peking Univ Hematol Instit
来源：
China Medical Abstracts(Internal Medicine) | 2020年 / 37卷 / 01期
关键词：
Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics;
D O I：
暂无
中图分类号：
R733.72 [慢性白血病];
学科分类号：
摘要：
Objective To compare the efficacy and safety of Chinese generic imatinib with branded imatinib as frontline therapy in adults with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)(Frontline group),and to explore the efficacy and safety of Chinese generic imatinib in CML-CP patients switching from branded imatinib (Switching group).Methods Frontline group:Data of adults with newly diagnosed CML-CP re-
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [41] Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study
    Bonifacio, Massimiliano
    Tiribelli, Mario
    Binotto, Gianni
    Miggiano, Maria Cristina
    Basso, Marco
    Calistri, Elisabetta
    Scaffidi, Luigi
    Stella, Rossella
    Frison, Luca
    Sartori, Roberto
    Ruggeri, Marco
    Semenzato, Gianpietro
    Fanin, Renato
    Krampera, Mauro
    BLOOD, 2019, 134
  • [42] Generic Imatinib in a Patients with Chronic Myeloid Leukemia in Chronic Phase- a Single Centre Experience
    Urosevic, Ivana M.
    Dokic, Marina
    Savic, Ivanka
    Savic, Aleksandar
    Milosevic, Ivana
    Rajic, Nebojsa
    Andjelkovic, Nebojsa V.
    Sekulic, Borivoj
    Vlaisavljevic, Nada V.
    BLOOD, 2014, 124 (21)
  • [43] Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia
    Wang, Qing
    Jiang, Zhi-Ping
    Zeng, Jing
    Zhu, Yan
    Cai, Hua-Lin
    Xiang, Da-Xiong
    He, Qun
    Shi, Xiao-Liu
    Zhong, An-Ni
    Zhao, Xie-Lan
    Xu, Ping
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2020, 23 : 1 - 9
  • [44] Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia
    Cole, Ashley L.
    Jazowski, Shelley A.
    Dusetzina, Stacie B.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (11) : 1529 - 1533
  • [45] Impact of Transition to Generic Imatinib in the Molecular Response Among Patients with Chronic Myeloid Leukemia
    Kang, Matthew
    Xenocostas, Anargyros
    Lazo-Langner, Alejandro
    Chin-Yee, Ian H.
    Howson-Jan, Kang
    Abouzeenni, Maisam
    Kovacs, Michael J.
    Hsia, Cyrus C.
    BLOOD, 2014, 124 (21)
  • [46] Comparison of combination therapy of imatinib with trisenox versus imatinib monotherapy for chronic myeloid leukemia patients in chronic phase.
    Yang, Dongguang
    Zhang, Ri
    Shen, Yunfeng
    Zhang, Xuhui
    Wu, De Pei
    BLOOD, 2006, 108 (11) : 612A - 612A
  • [47] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    Cortes, J.
    Kim, D-W
    Raffoux, E.
    Martinelli, G.
    Ritchie, E.
    Roy, L.
    Coutre, S.
    Corm, S.
    Hamerschlak, N.
    Tang, J-L
    Hochhaus, A.
    Khoury, H. J.
    Bruemmendorf, T. H.
    Michallet, M.
    Rege-Cambrin, G.
    Gambacorti-Passerini, C.
    Radich, J. P.
    Ernst, T.
    Zhu, C.
    Van Tornout, J. M. A.
    Talpaz, M.
    LEUKEMIA, 2008, 22 (12) : 2176 - 2183
  • [48] Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea
    Jain, Parveen
    Das, V. N. R.
    Ranjan, Alok
    Chaudhary, Rahul
    Pandey, Krishna
    JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2013, 2 (04) : 156 - 161
  • [49] Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
    J Cortes
    D-W Kim
    E Raffoux
    G Martinelli
    E Ritchie
    L Roy
    S Coutre
    S Corm
    N Hamerschlak
    J-L Tang
    A Hochhaus
    H J Khoury
    T H Brümmendorf
    M Michallet
    G Rege-Cambrin
    C Gambacorti-Passerini
    J P Radich
    T Ernst
    C Zhu
    J M A Van Tornout
    M Talpaz
    Leukemia, 2008, 22 : 2176 - 2183
  • [50] Persistence with Generic Imatinib for Chronic Myeloid Leukemia: A Matched Cohort Study
    Klil-Drori, Adi J.
    Yin, Hui
    Azoulay, Laurent
    Del Corpo, Alexa
    Harnois, Michael
    Gratton, Michel-Olivier
    Busque, Lambert
    Assouline, Sarit
    BLOOD, 2017, 130
12345